Bristol Myers Squibb
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. The company operates across the Americas, Europe, Asia Pacific and other regions, with emphasis on therapies in areas such as oncology, immunology and cardiovascular disease. Headquartered in the United States, BMS emphasizes patient care, research and collaboration to advance cancer treatment and other serious conditions.
Recent News
Bristol Myers Draws Pipeline Excitement as Several Data Readouts Near
Keep an Eye on These 15 Biotech Companies in 2026
After Exiting 2seventy, Chip Baird Took a 180 to Food Allergy With Newly Launched Poplar
Biotech in 2025: A Retrospective
BMS, Hengrui Ink $15.2B Oncology Deal Covering 13 Programs
Oxford BioTherapeutics Partners with BMS to Develop Next-Generation T-Cell Engagers for Solid Tumors
Replimune Cries Foul on Regulatory Flexibility. But Many Americans Want a Stricter FDA
Trophy Office Rents Jump 9% In D.C. For The Second Year In A Row
STAT+: Novartis CEO Joins Anthropic’s Board
TerraPower Commits $450M to Build Radioisotope Production Plant
Breast Cancer Treatments Heat Up: Six Therapies Poised to Transform Patient Outcomes
US Drug-Maker Ardelyx Hires Long-Time Bristol Myers Squibb Lawyer as Next CLO
BMS Signs $15.2 B Deal with China's Hengrui on 13 Drug Programs
Insilico Medicine Welcomes Dr. Halle Zhang as New Vice President of Clinical Development for Oncology
Brepocitinib Approval May Be ‘Highlight of the Derm-Rheum World’
#JPM26: Q&A with Bristol Myers Squibb CEO Chris Boerner on 2026 Outlook
BMS Beats Again Despite Eliquis and Cobenfy Disappointments
Coya 302 Gets Fast-Track Designation for ALS Treatment
BMS Partners with Hengrui Pharma in a Potential ~$15.2B Deal to Advance 13 Early-Stage Programs Across Oncology, Hematology, and Immunology
BMS Brings the Buzz Around Late-Stage Readouts Amid a So-So Q1
BofA Raises Cytokinetics Price Target on ACACIA Trial Results
Makary Resigns, BMS Bets $15B on China R&D, and Regenxbio Wins Phase 3 in Duchenne – This Week in Biotech #100
Zotatifin
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (Deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults
Trump’s New Drug Advertising Proposals Fall Short on Public Health and the Constitution
Novo Launches Oral Obesity Pill, Lilly Targets Lofty Revenue, FDA and M&A in Focus
Immunotherapy in Locally Advanced HNSCC: Is There Still Room for New Agents?
Medicare Can Save $4 Billion On Four Cancer Drugs – Can You Guess Which Ones?
Bristol Myers Squibb and Johnson & Johnson Launch Educational Program for Thromboembolic R&D
Bristol Myers Says Second CELMoD Succeeds in Phase 3
IDEAYA and Servier’s Eye Cancer Drug Heads to FDA After Delivering ‘Best in Class’ Efficacy
Incyte Wavers As Growth Questions Plague Its Up-And-Coming Drug
Why Owning the Learning Loop Matters More Than Owning the Lab
Regeneron Basks in First Gene Therapy Approval as Dupixent, Eylea Carry Robust Q1 Earnings
Hikma V. Amarin: The Amici Speak – Part II
Merck to Acquire Terns Pharmaceuticals for $6.7 B, Accelerating M&A Ahead of Keytruda Patent Expiry
Proteasomes: A Novel Approach to Target the Immune System
BMS Bets $850M on Janux’s Tumor-Activated Drugs, Deepening Cancer Investments
CMS's Medicare Price Negotiations Start Round Three
Sarepta, Amylyx and Neumora Look Ahead to Key Catalysts as Q1 Earnings Roll In
STAT+: Hims’ Sales Miss as Telehealth Competition Grows
Early Data Show Benefits of GLP-1s in Breast Cancer
AI Giant Anthropic Leans Into Life Sciences With $400M Coefficient Bio Catch
Report Says MSD Is in Talks to Buy Revolution Meds
What Does 17 Pharma MFN Deals Are Underneath the Press Releases: The Real Primary Source Stack, the GLP1 Numbers, TrumpRX Plumbing, and Where the New Adjudication Layer Gets Monetized
GSK Joins Growing PD-1 SubQ Push With Alteogen Alliance Worth up to $285M+
Evinova and Bristol Myers Squibb Launch AI Collaboration for Clinical Trials
An Analysis of International Space Station Experiments
What the Smart Money Just Bought in Healthcare and Life Sciences VC Over the Last Sixty Days
Proliferating Patents, Lawsuits Stave Off Pharmas’ Generic Competitors